Jennifer Fu, MD
Dermatology · El Cerrito, CANPI 1619000791
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Pfizer accounts for 63.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $6,664 and has fallen 89.1% since, to $723 in 2025.
Across 155 payments — averaging $110.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$11K
- Lilly USA, LLC$4K
- AbbVie$1K
- Johnson & Johnson$270
- Astellas Pharma US Inc$116
- Novartis$109
- plus $491 from 14 others
Across 12 payments — averaging $3501.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$42K
What the payments were for
- Consulting fees$6,43837%
- Speaking & faculty fees$6,60038%
- Travel & lodging$6764%
- Food & beverage$3,47420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $10,890 |
| Lilly USA, LLC | 36 | $4,276 |
| AbbVie | 44 | $1,035 |
| Johnson & Johnson | 17 | $270 |
| Astellas Pharma US Inc | 1 | $116 |
| Novartis | 6 | $109 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| Sun Pharmaceutical Industries Inc. | 3 | $67 |
| UCB, Inc. | 2 | $47 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $45 |
| Botanix SB Inc | 2 | $41 |
| Surgenex LLC | 1 | $34 |
| Dermavant Sciences, Inc. | 1 | $33 |
| Mimedx Group, Inc. | 1 | $29 |
| Strata Skin Sciences, Inc. | 2 | $27 |
| Sanofi | 1 | $24 |
| LEO Pharma Inc. | 1 | $22 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Medline Industries LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,187 in reported general payments places this provider in the 85th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Minoxidil | 229 | $3,964 |
| Hydroxychloroquine Sulfate | 54 | $1,028 |
| Doxycycline Hyclate | 19 | $885 |
| Mupirocin | 118 | $881 |
| Ketoconazole | 11 | $118 |
Paid to pharmacies, not to this prescriber.
Other dermatology in El Cerrito
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.